ARWR 241220 16.00C (ARWR241220C16000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

ARWR241220C16000

Watchlist

7.62
0.000.00%

15min DelayTrading Nov 27 09:45 ET

0.00High0.00Low

Intraday

5D
Daily

News

Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones12:17 ET · Ratings
Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.
Dow Jones12:17 ET · Ratings
Arrowhead Pharma Analyst Ratings
Benzinga12:04 ET · Ratings
Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment
MT NewswiresDec 3 08:28 ET
Express News | Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Alk7 for the Treatment of Obesity
ReutersDec 3 07:30 ET
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
BusinesswireDec 2 07:30 ET

Comments

Andrew Whiteside

Nov 22 09:29

$Arrowhead Pharmaceuticals (ARWR.US)$ $50

stockhub

Apr 7 11:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals (ARWR.US)$

Mooers' Insights

Tonyco

Apr 6 22:01

$Arrowhead Pharmaceuticals (ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

Mar 8 05:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

zulia3003

Mar 7 11:34

$Arrowhead Pharmaceuticals (ARWR.US)$ why drop today?